Your browser doesn't support javascript.
loading
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists.
Ibrahim, Mohammed K; Eissa, Ibrahim H; Abdallah, Abdallah E; Metwaly, Ahmed M; Radwan, M M; ElSohly, M A.
Afiliación
  • Ibrahim MK; Pharmaceutical Chemistry Departments, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
  • Eissa IH; Pharmaceutical Chemistry Departments, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt. Electronic address: Ibrahimeissa@azhar.edu.eg.
  • Abdallah AE; Pharmaceutical Chemistry Departments, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
  • Metwaly AM; Pharmacognosy Department, Faculty of Pharmacy (Boys), University of Al-Azhar, Cairo 11884, Egypt.
  • Radwan MM; National Center for Natural Products Research, University of Mississippi University, MS 38677, USA.
  • ElSohly MA; National Center for Natural Products Research, University of Mississippi University, MS 38677, USA. Electronic address: Melsohly@olemiss.edu.
Bioorg Med Chem ; 25(4): 1496-1513, 2017 02 15.
Article en En | MEDLINE | ID: mdl-28117121
ABSTRACT
In our effort to develop potent anti-hyperglycemic agents with potential agonistic activities toward PPARγ and SUR, three novel series of quinoxaline derivatives bearing sulfonylurea or sulfonylthiourea moieties with different linkers were designed and synthesized. Some of the newly synthesized compounds were evaluated in vivo for their anti-hyperglycemic activities in STZ-induced hyperglycemic rats. Compounds 15a, 15e, 19b and 24a exhibited the highest anti-hyperglycemic activities with % reduction in blood glucose level of (50.58, 43.84, 45.10 and 49.62, respectively). Additionally, eight compounds revealed potent anti-hyperglycemic activities were further evaluated in vitro for their PPARγ binding affinity and insulin-secreting ability as potential mechanisms for anti-hyperglycemic activity. Four compounds (15a, 15b, 15d and 15e) significantly bound to PPARγ with IC50 values of 0.482, 0.491, 0.350 and 0.369µM, respectively. Moreover, Compounds 15a and 15b have demonstrated induction of insulin-secretion with EC50 values of 0.92 and 0.98µM, respectively. Furthermore, molecular docking and pharmacophore generation techniques were carried out to investigate binding patterns and fit values of the designed compounds with PPARγ and SUR, respectively.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Quinoxalinas / Diseño de Fármacos / PPAR gamma / Receptores de Sulfonilureas / Hiperglucemia / Antihipertensivos Límite: Animals Idioma: En Revista: Bioorg Med Chem Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2017 Tipo del documento: Article País de afiliación: Egipto

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Quinoxalinas / Diseño de Fármacos / PPAR gamma / Receptores de Sulfonilureas / Hiperglucemia / Antihipertensivos Límite: Animals Idioma: En Revista: Bioorg Med Chem Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2017 Tipo del documento: Article País de afiliación: Egipto